facebook linkedin twitter

Dog Cancer Treatment Gets Green Light from FDA

July 21, 2021 by Daniel Mollenkamp

WASHINGTON – Dog-owners whose pets are diagnosed with a common form of cancer now have a federally approved treatment option. 

That new treatment, the first fully approved drug for canine lymphoma, has shown the conditional track of animal medicine can fulfill its mission to greenlight treatments for rare animal diseases, according to the U.S. Food and Drug Administration. 

The FDA gave the first full approval last week to a treatment for lymphoma in dogs. The treatment, Tanovea (rabacfosadine injection), is the first new animal drug available under conditional approval to become fully approved, according to materials from the agency.

The company associated with the newly approved drug, VetDC, Inc., has claimed that Tanovea has “demonstrated a 77% overall response and a 45% complete response rate, supporting a reasonable expectation of efficacy in both naïve and relapsed/refractory lymphoma.” 

Another company, Elanco Animal Health, will be the exclusive distributor of TANOVEA-CA1, after a development and commercialization agreement with VetDC.

Tanovea had already received “conditional approval” under an FDA program for animal treatments in 2016. 

Conditional approval is a designation that lets drug companies sell pet medicine that hasn’t yet been proven to meet the FDA’s full requirements for diseases, which is allowed under 2004 Congressional legislation. That 2004 legislation, the Minor Use and Minor Species Animal Health Act, was meant to make medicine available to pets that don’t have a lot of options, according to the FDA. 

It had tried to accomplish this by increasing the amount of legally approved medicine for minor species, such as ferrets and fish, and for minor uses in major species, like treating cancer in dogs, the FDA has said. In both cases, it wanted to make drugs that there wasn’t much of a financial incentive to pursue, easier to bring to market. It was expanded in 2018 to include more drugs in the conditional pathway, which the agency has said is a “main provision” of the law. 

The legislation was also created to eliminate the “financial roadblocks” pharmaceutical companies face in trying to bring “limited-demand animal drugs” to the market, the FDA said.

Globally, the animal medicines market has grown consistently since 2015 and has been projected to keep growing as well, with especially pronounced growth in the U.S.

Lymphoma is considered a disease of the immune system that grows in “lymphocytes,” a kind of white blood cell, the FDA said. It can affect any organ in the body, but it is most common in organs attached to the function of the immune system, according to written materials from the agency. The symptoms of the disease for dogs vary, and its causes are not presently known. 

According to the American Kennel Club, lymphoma is a common cancer in dogs and is similar to the disease in humans. The same chemotherapy protocols can be used in both humans and dogs. A spokesperson for the FDA has said that lymphoma represents as much as 24% of all cancer in dogs.

While a significant and relatively common form of canine cancer, it still only affects about 70,000 dogs a year, according to materials from the FDA. For context, the American Veterinary Medical Association estimates that there are more than 48 million households in the U.S. that own dogs, almost 40% of the population, making up a total of just shy of 77 million pet dogs in the country.

The FDA touts the approval as a vindication of its conditional pathway.

“This gives veterinarians another important tool to help extend the quality of life for dogs with lymphoma, and potentially give them and their owners more time together,” said Steven M. Solomon, director of the FDA’s Center for Veterinary Medicine.

The FDA has indicated that it hopes to use the pathway more in the near future.

“We’re committed to continue using all our authorities to help make limited-demand treatment options available to our animal companions,” Acting FDA Commissioner Janet Woodcock said. 

A+
a-

Regulation

December 7, 2021
by Dan McCue
Senate Confirms Rosenworcel as Next FCC Chair

WASHINGTON — Jessica Rosenworcel has been reappointed as FCC commissioner, making her the first female chair in the agency’s nearly... Read More

WASHINGTON — Jessica Rosenworcel has been reappointed as FCC commissioner, making her the first female chair in the agency’s nearly 90-year history. The Senate vote on Tuesday was 68-31. In a floor speech shortly beforehand, Senate Majority Leader Chuck Schumer, D-N.Y., called Rosenworcel “a remarkable, highly... Read More

December 1, 2021
by Tom Ramstack
Supreme Court Case Hints at Change In Federal Agency Regulation Decisions

WASHINGTON — Conservative judges on the Supreme Court suggested this week during arguments in a multibillion-dollar lawsuit over Medicare drug... Read More

WASHINGTON — Conservative judges on the Supreme Court suggested this week during arguments in a multibillion-dollar lawsuit over Medicare drug reimbursement that now might be the time to overturn a decades-old guiding principle of administrative law. The issue in American Hospital Association v. Becerra is a... Read More

November 30, 2021
by Dan McCue
FDA Panel Narrowly Approves Merck COVID-19 Pill

WASHINGTON — An advisory panel for the Food and Drug Administration narrowly approved the use of a COVID-19 pill manufactured... Read More

WASHINGTON — An advisory panel for the Food and Drug Administration narrowly approved the use of a COVID-19 pill manufactured by Merck. If the agency accepts the recommendation, molnupiravir would be the first drug Americans could be prescribed and take at home to treat the virus.... Read More

November 23, 2021
by Dan McCue
Pixstory Striving to Address the Need for User Safety On Social Media

WASHINGTON - Social media, once a venue for pet pictures and catching up with friends from high school, has turned... Read More

WASHINGTON - Social media, once a venue for pet pictures and catching up with friends from high school, has turned toxic in many cases. And it’s almost impossible to escape the most divisive of political commentary. Among those trying to address the issue is Appu Esthose... Read More

November 23, 2021
by Dan McCue
FEC Approves Rental of Schiff Campaign Email List to Promote New Book

WASHINGTON — Rep. Adam Schiff, D-Calif., is free to rent the email list compiled by his principal campaign committee, Schiff... Read More

WASHINGTON — Rep. Adam Schiff, D-Calif., is free to rent the email list compiled by his principal campaign committee, Schiff for Congress, to promote his new memoir, “Midnight in Washington,” the Federal Election Commission said in an advisory opinion announced Wednesday. Random House, a division of... Read More

November 17, 2021
by Dan McCue
Biden Administration Suspends Enforcement of Vaccine Mandate

WASHINGTON — The Biden administration on Wednesday suspended enforcement of a vaccine mandate on private companies with 100 or more... Read More

WASHINGTON — The Biden administration on Wednesday suspended enforcement of a vaccine mandate on private companies with 100 or more employees. The decision, which was carried out through the Occupational Safety and Health Administration, comes less than a week after the 5th U.S. Circuit Court of... Read More

News From The Well
scroll top